What Exelixis (EXEL) Investors Need to Know

Exelixis logged a -8.7% change during today's afternoon session, and is now trading at a price of $19.28 per share. On average, analysts give it a target price of $25.76.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The mid-cap company is based in the United States.

What to Consider if You Are Thinking of Buying Exelixis:

  • Exelixis has moved 18.0% over the last year.

  • EXEL has a forward P/E ratio of 20.7 based on its EPS guidance of 0.93.

  • Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 2.3%.

  • The company has a price to earnings growth (PEG) ratio of 0.66.

  • Its Price to Book (P/B) ratio is 2.44

Exelixis Has Irregular Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023-02-07 362,614 -27,706 390,320 -14.22
2022-02-18 400,804 -54,225 455,029 90.13
2021-02-11 208,982 -30,345 239,327 -55.66
2020-02-25 526,956 -12,834 539,790 20.3
2019-02-22 415,720 -32,989 448,709 140.48
2018-02-26 165,611 -20,979 186,590

Exelixis's free cash flows have a decent average of $376.63 Million over the last 6 years, but they are highly variable since their coefficient of variability is 452305452.2%. The compounded average growth rate over this period is 0.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

ON FOCUS